We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current BGNE market cap is 202.36B. The company's latest EPS is USD -0.6486 and P/E is -19.40.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 447.8M | 595.26M | 781.31M | 634.41M | 751.65M |
| Operating Income | -371.26M | -318.72M | -133.97M | -383.8M | -261.35M |
| Net Income | -348.43M | -381.14M | 215.41M | -367.55M | -251.15M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 428.21M | 308.87M | 1.18B | 1.42B | 2.46B |
| Operating Income | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B |
| Net Income | -948.63M | -1.6B | -1.41B | -2B | -881.71M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.96B | 5.73B | 5.52B | 5.81B | 5.67B |
| Total Liabilities | 1.8B | 1.93B | 1.76B | 2.27B | 2.31B |
| Total Equity | 4.16B | 3.8B | 3.76B | 3.54B | 3.36B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.61B | 5.6B | 8.65B | 6.38B | 5.81B |
| Total Liabilities | 633.93M | 1.73B | 2.4B | 2B | 2.27B |
| Total Equity | 978.36M | 3.87B | 6.24B | 4.38B | 3.54B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -563.78M | -857.67M | -935.82M | -1.16B | -308.57M |
| Investing | 241.06M | 308.86M | 122.59M | 60M | -209.83M |
| Financing | -19.87M | 146.21M | 69.43M | 416.48M | 162.29M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -750.27M | -1.28B | -1.3B | -1.5B | -1.16B |
| Investing | 554.16M | -3.17B | 640.66M | 1.08B | 60M |
| Financing | 85.68M | 5.2B | 3.64B | -18.97M | 416.48M |
| Market Cap | 202.36B |
| Price to Earnings Ratio | -19.40 |
| Price to Sales Ratio | 6.96 |
| Price to Cash Ratio | 5.39 |
| Price to Book Ratio | 4.83 |
| Dividend Yield | - |
| Shares Outstanding | 1.36B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 16.9 (10.43%) |
| Company Name | BeiGene Ltd |
| Address |
94 solaris avenue grand cayman KY1 1104 |
| Website | https://www.beigene.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
